INTRODUCTION
Chronic obstructive pulmonary disease (COPD) affects over 12 million adults in the United States and is the third leading cause of both death and 30-day readmissions [1] [2] [3] [4] . Direct COPD costs are almost $50 billion in the United States annually [2, [5] [6] [7] [8] [9] [10] , whereas total COPD care-related costs can be up to double the identified direct costs because of comorbid diseases and indirect costs such as lost work days [11] [12] [13] . Acute exacerbations of COPD (AECOPD) are responsible for up to 70% of COPD-related healthcare costs; hospital readmissions alone account for over $15 billion in direct costs annually [2, 3, [6] [7] [8] 11, 13] . As readmissions are costly and many are considered preventable, there have been recent federal efforts targeting reductions [2, 9, 14] . In 2014, the Centers for Medicare and Medicaid (CMS) instituted financial penalties for hospitals with excessive readmissions, defined as more-than-expected (per prespecified calculations), within 30 days of index AECOPD hospitalizations [9] . This Hospital Readmissions Reduction Program (HRRP) began to change the incentives for COPD care. For instance, some hospitals may incur costs to provide care that would not specifically be reimbursed under Medicare's Prospective Payment System with the hope that such care would decrease readmissions and lead to lower financial penalties. In addition, innovative payment paradigms are being introduced that may influence the cost-benefit ratio of readmission reduction programs. For example, the voluntary CMS Bundled Payment Care Initiative (BPCI) provides a set Medicare payment for an episode of care across providers and sectors that would normally be paid separately, such as payment for a hospital admission and postacute care. Similarly, accountable care organizations (ACOs), in which a provider group accepts responsibility for all costs of care across sectors for a panel of patients, are also changing the funding landscape and potentially care delivery. In addition to the economic burden on hospitals and payers, patients are affected by both direct and indirect costs associated with COPD readmissions [15] .
In this review, we aim to describe insights about the economic impact of COPD readmissions post-HRRP based on articles published between January 2016 and August 2017 that provide insight into the economic impact of COPD readmissions in the United States, focused on both the direct financial costs and the broader context of indirect effects and opportunity costs.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE READMISSION RATES
In the United States, prior to the recent federal penalty programs and focus on reducing readmissions [9] , nearly one-quarter of Medicare patients admitted to the hospital with AECOPD were readmitted within 30 days [2] . Readmissions after AECOPD are not always for recurrent/ongoing AECOPD, as only about one-quarter to one-third are related to underlying COPD [2, 10] .
FACTORS RELATED TO INCREASED RISK OF READMISSION
To implement interventions to reduce readmissions, it is critical to identify patients at high risk of readmission and their potential economic impact. Among articles published in the last 18 months, select insights have emerged that may be helpful whenever considering economic factors related to COPD readmissions.
Younger patients on public insurance at higher risk for readmission
In one study of the Healthcare Cost and Utilization Project (HCUP) State Inpatient Database for California (years 2005-2011), the authors evaluated all readmissions for COPD across all ages and payer status [16 & ]. There were more than 28 million visits across almost 18 million patients over 480 hospitals in the dataset. Among these data, they found 286 313 hospitalizations for patients aged 40 years or older with a primary COPD diagnosis discharged alive. They found that patients aged 40-64 with public insurance had the highest rates of readmission (14.77% Medicare; 16.7% Medicaid). However, patients in this age group with private insurance had the lowest rate (8.25%).
Countering this is an earlier study prior to the period included in this review that examined age as one risk factor for readmission because of AECOPD [17] . Patients (n ¼ 2138) in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) observational cohort were examined over a 3-year follow-up; prior history of
KEY POINTS
The highest economic burden of COPD is from AECOPD leading to hospitalization and readmissions; high-symptom burden, multimorbidity, and disease severity are important drivers of cost and morbidity associated with AECOPD care utilization.
The evidence on what works to reduce COPD readmissions is still quite sparse, reflecting significant uncertainty around this question; for instance, the HRRP was implemented and extended to COPD despite a dearth of evidence, so it will take time for the evidence base to reach maturity.
Inter-professional-led teams with nurses or respiratory therapists show promise at helping to reduce readmissions, but cost analyses to provide these interventions were not published.
Multidisciplinary team-based and bundled interventions had variable results: some found improved quality of care delivered without decreased readmissions, others found readmission rates that varied by level of care quality, which is interesting because the HRRP is a financial penalty, directly reducing hospital revenues, yet hospitals in response are pursuing interventions that often include upfront programmatic costs to reduce readmissions without direct evidence on whether these interventions will actually work and may or may not outweigh savings from reduced penalties.
As evidence on effective interventions becomes stronger, there will be increased attention to cost, however, to date, most published interventions developed in response to the penalty did not provide cost analyses; those that did had variable findings from no cost savings to considerable cost-savings.
AECOPD was associated with the highest risk of a new hospitalization for exacerbation and increased mortality risk. In this group, both poorer health status and older age were also associated with an increased risk of hospital admission. The conflicting studies based on age may relate to differences in methodologies, but highlight the importance of considering age and insurance status (serving in part as a proxy for socioeconomic status and unmeasured health characteristics, in addition to payer-specific financial incentives), in any intervention protocol to reduce readmissions for AECOPD.
Prolonged hospital course an important factor for readmission ]. The primary predictors included baseline chronic respiratory failure, low peripheral oxygen saturation at initial presentation in the index admission, poor glycemic control, and sputum cultures positive for bacterial growth. These factors were predictive independent of age, BMI, comorbidity, and baseline exercise capacity. No studies done to date have explored whether aggressive control or treatment of these factors leads to a reduction in readmission risk.
DRIVERS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE CARE COSTS IN THE UNITED STATES
In addition to identifying risk factors specific to readmissions, risks related to having COPD and their impact on overall COPD-related costs are important to identify whenever considering programs targeting reductions of COPD readmissions.
High-symptom burden likely drives costs
In a study of patients in a managed care system, the authors found that patients with COPD who had high COPD-related symptomology had increased use of healthcare resources resulting in higher COPD-related healthcare costs for inpatient hospitalizations, emergency room visits, office visits, and prescription medications [20 & ]. Although not specific to readmission risk, it is reasonable to assume that a high-symptom burden, indicative of more severe COPD, is a marker of increased risk of subsequent admissions.
Certain comorbidities increase healthcare related utilization and resulting costs
It has been well documented that patients with COPD frequently suffer from comorbid diseases [21,22,23
& ]. In one study, 98% of patients with COPD had at least one comorbidity and 54% had four or more comorbidities [22] . Multimorbidity is important to consider whenever implementing interventions to reduce readmissions after AECOPD. For instance, readmissions for heart failure, acute myocardial infarction, pneumonia, and stroke were all correlated with readmissions for COPD [23 & ]. Several of these diagnoses also fall under the CMS HRRP including CHF, PNA, and AMI [9] . In a study of Medicare patients, most comorbidities [anxiety disorders, cerebrovascular disease, congestive heart failure (CHF), coronary artery disease, depressive disorders, osteoarthritis, osteoporosis, sleep apnea, type 2 diabetes] were associated with higher allcause healthcare costs, the exceptions being chronic kidney disease and obesity. Whenever evaluating for COPD-related healthcare costs, CHF, sleep apnea, anxiety disorders, and osteoporosis were associated with higher total COPD costs [24
One recent comorbidity that has gained attention among other chronic diseases is frailty. In a study evaluating readmission risks among patients with CHF, frail patients were more likely to be readmitted [25] . It is tempting to suggest a similar relationship between frailty and COPD; this will require study in the future.
Low FEV1 predicted levels place patients at higher risk for incurring chronic obstructive pulmonary disease-related healthcare costs Although prior studies have demonstrated a relationship between poor lung function and higher costs, such studies had been limited to small sample sizes, were conducted outside the United States, were conducted over a decade ago, and/or were single-center sites [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . One study published in the last eighteen months evaluated the impact of Forced expiratory volume in one second (FEV1) levels on health-care-related utilizations among a United States managed care population [39 & ]. This retrospective, observational study examined both administrative claims and spirometry on patients from 14 geographically dispersed United States health plans from 2011 to 2014. In this study, patients with a baseline FEV1 less than 50% predicted had higher COPD-related healthcare costs, and costs were driven both by more frequent AECOPD (resulting in greater healthcare utilization) and higher pharmacy claims [39 & ]. Poor lung function, then may be one driver of healthcare costs for COPD and specifically for AECOPD.
HOSPITAL-BASED INTERVENTIONS
To respond to the CMS HRRP, it is important to identify programs that are effective at reducing readmissions, and ideally in a cost-neutral or costsaving manner (Table 1) .
Avoiding index hospitalizations
One way to reduce readmissions is to avoid initial index admissions [40 && ]. Prior studies from before the review period, for example, have shown that the use of influenza vaccination has been demonstrated to reduce hospitalizations for COPD both in the United States and elsewhere [41] [42] [43] [44] [45] [46] ; indeed, vaccination is considered a cornerstone of care in the GOLD COPD guidelines [47] .
During the period included in this review, one study evaluated the use of home noninvasive ventilation (NIV) for COPD. The investigators found that this intervention provided nearly half a million dollars in savings over 30 ($402 981) and 90 days ($449 101) because of reduced admissions/readmissions. The authors concluded that use of NIV may provide an 'opportunity for hospitals to reduce COPD readmission-related costs' [40 && ]. Counterbalancing this is a recent meta-analysis examining home (domiciliary) NIV in patients with severe COPD [48 & ]. For stable patients, no evidence of a survival benefit from NIV could be demonstrated, whereas the literature was divided on a significant survival benefit in patients recently discharged for AECOPD. Likewise, effects on hospitalization and cost savings were inconsistent, with a trend in the data towards a benefit for patients with demonstrated hypercapnia. The parameters and timing for domiciliary NIV, thus remain to be determined.
Provider, service, service setting type may not result in different 30-day readmission rates
In one study evaluating Medicare patients' process and outcome measures by provider type (primary care physician versus advanced practice provider), in addition to a few process differences around medication prescriptions and consultations, no differences were found with respect to admissions or 30- . Despite these reductions in readmissions, cost analyses were not published. Future studies are needed to understand the value-based determinations, and specifically whether the savings generated by fewer readmissions are greater than the associated costs of the management model.
Bundled programs may improve process measures and quality of care provided; readmissions and cost results vary
One important consideration is whether the generation of a bundled program will both improve quality of care and lower costs. Evidence to date suggests mixed results in this regard. One study found decreased 30-day and 60-day readmissions and lower costs with a bundled program driven by the guideline recommendations for AECOPD hospitalbased care. Using this model, readmission rates were 9 versus 54% and 23 versus 77% at 30 and 60 days, respectively, for those receiving the bundle. It should be noted that the control group had readmission rates substantially higher than the national Studies that evaluated readmission rates and/or costs of intervention aimed at reducing readmissions.
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average. In addition, hospital costs at 90 days were significantly lower in the bundled care group ($7652 versus $19 954; P ¼ 0.04) [54 && ]. They also showed significant quality of care and process measure improvements. In contrast, another study that evaluated a comprehensive program that provided care across the hospital-to-home transition via a multidisciplinary team as part of a BPCI effort demonstrated no differences in 30-day or 90-day readmission rates or in cost savings, though process and quality measures improved. However, several process and intervention level differences existed in the findings between the studies, with improvements seen in the BPCI group including increased pulmonary rehabilitation referrals, appropriate smoking cessation referrals, among others [55 && ]. Finally, another program that evaluated multidisciplinary team-based intervention of a package of five bundled components found that patients receiving high-quality care, defined as receiving four or five of five prespecified components (see Table 1 ), had significantly lower readmission rates at 12.5 and 10.9% respectively, versus those receiving lower quality care (missing two or more components), with a rate of 26.5%. Although this study did not evaluate costs, they did find improved quality of care process measures, with an increase of 50-89% of bundle components provided [56 && ].
CONCLUSION
The literature identifies factors that may place patients at higher readmission risk, but is sparse with respect to effective interventions and cost analyses to assess whether intervention costs are outweighed by reduced HRRP financial impact. Most studies evaluated process, quality of care, and readmission outcomes, but did not usually include cost analyses. Interventions, particularly interdisciplinary teams with bundled care, aimed at reducing readmission were uniformly successful at improving quality of care provided and demonstrating improved process measures. However, success at reducing readmissions and cost savings based on these interventions varied across the studies. , the authors evaluated all readmissions for COPD across all ages and payer status. There were more than 28 million visits across almost 18 million patients over 480 hospitals in the dataset. Among these data, they found 286 313 hospitalizations for patients aged 40 years or older with a primary COPD diagnosis discharged alive. They found that patients aged 40-64 with public insurance had the highest rates of readmission (14.77% Medicare; 16.7% Medicaid). However, patients in this age group with private insurance had the lowest rate (8.25%). This study evaluated predictors of readmission after AECOPD demonstrated that a prolonged index AECOPD admission may put patients at higher risk for subsequent readmission. In this secondary analysis of the REDUCE cohort, a hospital stay of more than 8 days had a substantially increased readmission risk within 30 days (hazard ratio 1.54; 95% CI 1.03-2.28).
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